Document is current
Any future updates will be listed below
-
Authors
Perimbeti, Stuthi
Jamroze, Anmbreen
Gopalakrishnan, Dharmesh
Jain, Rohit
Jiang, Changchuan
Holleran, Julianne L.
Parise, Robert A.
Bies, Robert
Quinn, David
Attwood, Kristopher
Liu, Xiaozhuo
Green, Kelly
Kirk, Jason S.
Beumer, Jan H.
Tang, Dean G.
Chatta, Gurkamal
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03751436 at ClinicalTrials.govDocuments that mention this clinical trial
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer
https://doi.org/10.1007/s00280-025-04840-2
Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC).
https://doi.org/10.1200/jco.2023.41.6_suppl.182
-
Funding
Funding for this research was provided by:
National Cancer Institute (R50CA211241)
National Cancer Institute (R01CA237027)
U.S. Department of Defense (PC220137)
Prostate Cancer Foundation (PCF) Challenge Award (2022CHAL3788)
AbbVie
- License Information
-
More Information
Article History
Received: 23 May 2025
Accepted: 21 October 2025
First Online: 29 November 2025
Declarations
:
: The authors declare no competing interests.
